Legal & General Group Plc Sells 33,006 Shares of Globus Medical, Inc. $GMED

Legal & General Group Plc lowered its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 9.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 330,886 shares of the medical device company’s stock after selling 33,006 shares during the period. Legal & General Group Plc owned approximately 0.25% of Globus Medical worth $28,890,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of GMED. AQR Capital Management LLC grew its holdings in Globus Medical by 45.9% in the first quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock worth $1,622,000 after purchasing an additional 7,086 shares during the period. Integrated Wealth Concepts LLC grew its holdings in Globus Medical by 33.0% in the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock worth $320,000 after purchasing an additional 1,085 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Globus Medical by 38.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after purchasing an additional 8,540 shares during the period. Jones Financial Companies Lllp grew its holdings in Globus Medical by 237.3% in the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after purchasing an additional 598 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Globus Medical by 8.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock worth $25,439,000 after purchasing an additional 28,027 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Performance

NYSE GMED opened at $82.00 on Friday. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The stock has a 50-day moving average of $87.01 and a 200 day moving average of $88.41. The company has a market capitalization of $11.13 billion, a price-to-earnings ratio of 19.07, a PEG ratio of 1.69 and a beta of 1.00.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same period in the previous year, the firm earned $0.68 EPS. The business’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GMED. Truist Financial set a $115.00 price target on Globus Medical in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Finally, Needham & Company LLC lifted their price target on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.